KR890004720A - 성장 인자를 함유하는 겔 제형 - Google Patents

성장 인자를 함유하는 겔 제형 Download PDF

Info

Publication number
KR890004720A
KR890004720A KR1019880011968A KR880011968A KR890004720A KR 890004720 A KR890004720 A KR 890004720A KR 1019880011968 A KR1019880011968 A KR 1019880011968A KR 880011968 A KR880011968 A KR 880011968A KR 890004720 A KR890004720 A KR 890004720A
Authority
KR
South Korea
Prior art keywords
formulation
growth factor
group
sulfate
weight
Prior art date
Application number
KR1019880011968A
Other languages
English (en)
Inventor
엘·핀케노어 에이미
엠·코헨 조나단
더블유·샐라비 샐라비
에이·샌도발 엘리자베드
에스·베즈와다 라오
엘·크로넨탈 리차드
Original Assignee
원본미기재
에티콘 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 에티콘 인코포레이티드 filed Critical 원본미기재
Publication of KR890004720A publication Critical patent/KR890004720A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

내용 없음

Description

성장 인자를 함유하는 겔 제형
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 시간의 경과에 따른, 카보폴(Carbopol) 940, 플루로닉(Pluronic) F-127 및 HPMC-E4M을 함유하는 겔 제형으로부터의 EGF의 방출 %을 나타낸다.
제2도는 시간의 경과에 따른, 폴리아크릴아미드 겔 제형으로부터의 EGF의 방출 %을 나타낸다.
제3도는 시간의 경과에 따른, 폴리아크릴아미드/아가 겔리페륨(Geliperm ™) 상처 치료제로부터의 방출 %을 나타낸다.

Claims (41)

  1. a) 사람의 유사 분열 또는 맥관 형성 활성을 갖는 폴리펩타이드 성장 인자의 상처 치유 유효량, 및 b) 실온에서 1,000 내지 12,000,000 CPS 범위 내의 점도를 제공하기 위한 수용성 또는 수팽윤성의 약제학적으로 허용되는 중합체성 물질을 함유함을 특징으로 하는, 국소적 및 절개된 상처 치유를 위한 수성 겔 제형,
  2. 제1항에 있어서, 성장 인자가 표피 성장 인자, 전환(transforming) 성장 인자-α, 전환 성장인자-β, 염기성 섬유 아세포 성장 인자, 산성 섬유 아세포 성장인자, 인슐린형 성장 인자, 혈소판 유도 성장 인자, 이들의 생물학적 활성 단편 또는 유도체, 및 이들의 혼합물로 이루어진 그룹 중에서 선택되는 제형.
  3. 제2항에 있어서, 성장 인자가 표피 성장 인자인 제형.
  4. 제1항에 있어서, 성장 인자 농도가 약 0.01 내지 약 1,000μg/ml의 범위 내인 제형.
  5. 제1항에 있어서, 중합체가 비닐 중합체, 폴리옥시에틸렌-폴리옥시프로필렌 공중합체, 다당류, 단백질, 폴리(에틸렌 옥사이드), 아크릴아미드 중합체 및 이들의 유도체 또는 염으로 이루어진 그룹 중에서 선택되는 제형.
  6. 제5항에 있어서, 비닐 중합체가 폴리아클리산, 폴리메트아크릴산, 폴리비닐 피롤리돈 및 폴리비닐 알코올로 이루어진 그룹 중에서 선택되는 제형.
  7. 제5항에 있어서, 다당류가 셀루로즈 유도체, 글리코사미노글리칸, 아가, 알긴산, 텍스트란, 전분 및 키토산으로 이루어진 그룹 중에서 선택되는 제형.
  8. 제7항에 있어서, 글리코사미노글리칸이 히알우론산, 콘드로이틴, 콘드로이틴-4-설페이트, 콘드로이틴-6-설페이트, 데르마틴 설페이트, 케라틴 설페이트, 헤파린 설페이트 및 헤파린으로 이루어진 그룹 중에서 선택되는 제형.
  9. 제5항에 있어서, 담잭질이 콜라겐, 젤라틴 및 피브로넥틴으로 이루어진 그룹 중에서 선택되는 제형.
  10. 제5항에 있어서, 아크릴아미드 중합체가 폴리아클릴아미드 또는 폴리메트아크릴아미드인 제형.
  11. 제6항에 있어서, 비닐 중합체가 분자량이 약 450,000 내지 4,000,000인 폴리아크릴산 0.01 내지 5중량%인 제형.
  12. 제5항에 있어서, 중합체가 평균 분자량이 약 500 내지 50,000인 폴리옥시에틸렌-폴리옥시프로필렌 블럭 공중합체 15 내지 60중량%인 제형.
  13. 제7항에 있어서, 다당류가 분자량이 약 50,000 내지 700,000인 셀루로즈 유도체 1 내지 20중량%인 제형.
  14. 제8항에 있어서, 글리코사미노글리칸이 분자량이 약 500,000 내지 8,000,000인 히알우론산 0.5 내지 10중량%인 제형.
  15. a) 사람의 유사 분열 또는 맥관 형성 활성을 갖는 폴리펩타이드 성장 인자의 상처 치유 유효량, 및 b) 실온에서 10,000 내지 100,000 CPS 범위내의 점도를 제공하기 위한 수용성 또는 수팽윤성의 안과학적으로 적합한 중합체성 물질을 함유함을 특징으로 하는, 안전 수방(anterior chamber of the eye)의 상처 치유를 위한 수성 겔 제형.
  16. 제15항에 있어서, 성장 인자가 표피 성장인자, 전환 성장인자-α, 전환 성장인자-β, 염기성 섬유 아세포 성장 인자, 산성 섬유 아세포 성장 인자, 인슐린형 성장 인자, 혈소판 유도 성장 인자, 이들의 생물학적 활성단편 또는 유도체, 및 이들의 혼합물로 이루어진 그룹 중에서 선택되는 제형.
  17. 제16항에 있어서, 성장 인자가 표피 성장 인자인 제형.
  18. 제15항에 있어서, 성장 인자 농도가 약 0.01 내지 약 1,000μg/ml의 범위 내인 제형.
  19. 제15항에 있어서, 중합체가 다당류, 단백질, 아크릴아미드 중합체 및 이들의 유도체 또는 염으로 이루어진 그룹 중에서 선택되는 제형.
  20. 제19항에 있어서, 다당류가 셀루로즈 유도체, 글리코사미노글리칸, 아가, 알긴산, 덱스트란, 전분 및 키토산으로 이루어진 그룹 중에서 선택되는 제형.
  21. 제20항에 있어서, 글리코사미노글리칸이 히알우론산, 콘드로이틴, 콘드로이틴-4-설페이트, 콘드로이틴-6-설페이트, 데르마틴 설페이트, 케라틴 설페이트, 헤파린 설페이트 및 헤파린으로 이루어진 그룹 중에서 선택되는 제형.
  22. 제19항에 있어서, 단백질이 콜라겐, 젤라틴 및 피브로넥틴으로 이루어진 그룹 중에서 선택되는 제형.
  23. 제19항에 있어서, 아크릴아미드 중합체가 폴리아크릴아미드 또는 폴리메트아크릴아미드인 제형.
  24. 제20항에 있어서, 다당류가 분자량이 약 50,000 내지 700,000인 셀룰로즈 유도체 1 내지 20중량%인 제형.
  25. 제21항에 있어서, 글리코사미노글리칸이 분자량이 약50,000 내지 8,000,000인 히알우론산 0.05 내지 5.0중량%인 제형.
  26. a)사람의 유사 분열 또는 맥관 형성 활성을 갖는 폴리펩타이드 성장 인자의 상처 치유 유효량, 및 b) 실온에서 1 내지 5,000 CPS 범위 내의 점도를 제공하기 위한 수용성 또는 수팽윤성의 약제학적으로 또는 인과학적으로 허용되는 중합체성 물질을 함유함을 특징으로 하는 수성 제형.
  27. 제26항에 있어서, 성장 인자가 표피 성장 인자, 전환 성장 인자-α, 전환 성장 인자-β, 염기성 섬유 아세포 성장 인자, 산성 섬유 아세포 성장 인자, 인슐린형 성장 인자, 혈소판 유도 성장 인자, 이들의 생물학적 활성 단편 또는 유도체, 및 이들의 혼합물로 이루어진 그룹 중에서 선택되는 제형.
  28. 제27항에 있어서, 성장 인자가 표피 성장 인자인 제형.
  29. 제26항에 있어서, 성장 인자 농도가 약 0.01 내지 약 1,000β g/ml의 범위 내인 제형.
  30. 제26항에 있어서, 중합체가 비닐 중합체, 폴리옥시에틸렌-폴리옥시프로필렌 공중합체, 다당류, 단백질, 폴리(에틸렌 옥사이드), 아크릴아미드 중합체 및 이들의 유도체 또는 염으로 이루어진 그룹 중에서 선택되는 제형.
  31. 제30항에 있어서, 비닐 중합체가 폴리아크릴산, 폴리메트아크릴산, 폴리비닐 피롤리돈 및 폴리비닐 알코올로 이루어진 그룹 중에서 선택되는 제형.
  32. 제30항에 있어서, 다당류가 셀룰로즈 유도체, 글리코사미노글리칸, 아가, 알긴산, 덱스트란, 전분 및 키토산으로 이루어진 그룹 중에서 선택되는 제형.
  33. 제32항에 있어서, 글리코사미노글리칸이 히알우론산, 콘드로이틴, 코드로이틴-4-설페이트, 콘드로이틴-6-설페이트, 데르마틴 설페이트, 케라틴 설페이트, 헤파린 설페이트 및 헤파린으로 이루어진 그룹 중에서 선택되는 제형.
  34. 제30항에 있어서, 단백질이 콜라겐, 젤라틴 및 피브로넥틴으로 이루어진 그룹 중에서 선택되는 제형.
  35. 제30항에 있어서, 아크릴아미드 중합체가 폴리아크릴아미드 또는 폴리메트아크릴아미드인 제형.
  36. 제31항에 있어서, 비닐 중합체가 분자량이 약 100,000 내지 4,000,000인 폴리아크릴산 0.01 내지 2.0중량%인 제형.
  37. 제30항에 있어서, 중합체가 평균 분자량이 약 500 내지 500,000인 폴리옥시에틸렌-폴리옥시프로필렌블럭 공중합체 2 내지 40중량%인 제형.
  38. 제32항에 있어서, 다당류가 분자량이 80,000 내지 240,000인 셀룰로즈 유도체 1 내지 20중량%인 제형.
  39. 제33항에 있어서, 글리코사미노글리칸이 분자량이 약 50,000 내지 8,000,000인 히알우론산 0.5 내지 5.0중량%인 제형.
  40. 굴종 다공성 또는 미세 다공성 기질과 배합되어 있는 제1항의 제형.
  41. 굴종 다공성 또는 미세 다공성 기질과 배합되어 있는 제26항의 제형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880011968A 1987-09-18 1988-09-16 성장 인자를 함유하는 겔 제형 KR890004720A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9881687A 1987-09-18 1987-09-18
US?98,816? 1987-09-18
US23348388A 1988-08-19 1988-08-19
US?233,483? 1988-08-19

Publications (1)

Publication Number Publication Date
KR890004720A true KR890004720A (ko) 1989-05-09

Family

ID=26795141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880011968A KR890004720A (ko) 1987-09-18 1988-09-16 성장 인자를 함유하는 겔 제형

Country Status (9)

Country Link
US (1) US5427778A (ko)
EP (1) EP0312208A1 (ko)
JP (1) JPH02112A (ko)
KR (1) KR890004720A (ko)
AU (1) AU2223588A (ko)
GR (1) GR1000250B (ko)
MX (1) MX169808B (ko)
NZ (1) NZ226171A (ko)
PT (1) PT88541A (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100231805B1 (ko) * 1997-01-09 1999-12-01 윤재승 인간상피세포 성장인자를 함유하는 피부외용제 조성물
KR100748390B1 (ko) * 2005-11-14 2007-08-10 주식회사 대웅 상피세포성장인자를 포함하는 상처치료용 서방성 필름 제형

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124316A (en) * 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
CA2011423A1 (en) * 1989-03-07 1990-09-07 Peter M. Taylor Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5271943A (en) 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
LU87624A1 (fr) * 1989-11-16 1991-07-22 Oreal Composition pharmaceutique et/ou cosmetique contenant un facteur de croissance hypophysaire(hdgf)stabilise par de l'elastine soluble
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
WO1991016058A1 (en) * 1990-04-26 1991-10-31 Cytrx Corporation Composition and method for topical treatment of damaged or diseased tissue
CA2082420C (en) * 1990-05-30 2004-07-20 Harry N. Antoniades Wound healing composition comprising purified igf-i or igf-ii and a purified tgf-.beta.
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
GB2248842A (en) * 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
US5955436A (en) * 1990-11-20 1999-09-21 Alcon Laboratories, Inc. Use of platelet derived growth factor to enhance wound healing
EP0564502B1 (en) * 1990-11-27 2002-01-30 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7208179B1 (en) 1990-11-27 2007-04-24 The American National Red Cross Methods for treating disease and forming a supplemented fibrin matrix
SE501217C2 (sv) * 1990-12-06 1994-12-12 Skandigen Ab Cellproliferationsmatris och användning därav
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
GB9102107D0 (en) * 1991-01-31 1991-03-13 Erba Carlo Spa Stabilisation of fibroblast growth factor using a polysaccharide
GR920100122A (el) * 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
EP0510270A1 (en) * 1991-04-25 1992-10-28 LINDSTROM, Richard L. Viscoelastic solution
EP0516026A1 (en) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel and method of producing same
JP3305355B2 (ja) * 1991-06-03 2002-07-22 三菱化学株式会社 肝実質細胞増殖剤
TW318142B (ko) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
WO1992022304A1 (en) * 1991-06-14 1992-12-23 Amgen Inc. Collagen film drug delivery for proteins
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
FR2678832B1 (fr) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
EP0608320B1 (en) * 1991-10-16 1998-01-28 Richardson-Vicks, Inc. Enhanced skin penetration system for improved topical delivery of drugs
WO1993007856A1 (en) * 1991-10-16 1993-04-29 Richardson-Vicks, Inc. LOW pH AQUEOUS COSMETIC GEL CONTAINING NON-IONIC POLYACRYLAMIDE DERIVATIVES
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
CA2080537A1 (en) * 1991-10-21 1993-04-22 David B. Volkin Stabilized topical acidic fibroblast growth factor formulation
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
DE4209722C3 (de) * 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
WO1994002176A1 (en) * 1992-07-28 1994-02-03 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
FR2699545B1 (fr) * 1992-12-18 1995-01-27 Oreal Agent gélifiant résultant de l'association d'un chitosane et d'un alginate d'alkyle ou d'hydroxyalkyle et son utilisation dans la préparation de compositions cosmétiques et pharmaceutiques.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ATE203913T1 (de) * 1993-05-31 2001-08-15 Kaken Pharma Co Ltd Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
US5989536A (en) * 1993-07-03 1999-11-23 The Procter & Gamble Company Personal cleansing compositions containing alkoxylated ether and cationic ammonium salt for deposition of active agent upon the skin
CU22405A1 (es) * 1993-07-05 1996-01-31 Cigb Composicion cosmetica para el cuidado de la piel
AU697894B2 (en) * 1993-11-09 1998-10-22 Neurospheres Holdings Ltd (In situ) modification and manipulation of stem cells of the central nervous system
US20030105007A1 (en) * 1995-06-07 2003-06-05 Andre Beaulieu PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
EP0830381A4 (en) * 1995-06-09 2000-11-22 William N Drohan CHITINE HYDROGELS, PRODUCTION METHOD AND USE
JPH09143093A (ja) * 1995-11-17 1997-06-03 Hoechst Japan Ltd 軟骨・骨誘導性修復用材料
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
JP2000506165A (ja) * 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US5942499A (en) * 1996-03-05 1999-08-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6630442B1 (en) * 1997-01-10 2003-10-07 Theodore Hersh Reparatives for chemosurgery and laser (thermal) therapy
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
US6138683A (en) * 1997-09-19 2000-10-31 Thione International, Inc. Smokeless tobacco products containing antioxidants
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
BR9815708B1 (pt) * 1998-03-07 2010-10-19 composição tópica para tratar lesões cutáneas.
US20030147860A1 (en) 2002-02-07 2003-08-07 Marchosky J. Alexander Compositions and methods for forming and strengthening bone
US6497893B1 (en) 1999-06-30 2002-12-24 Kimberly-Clark Worldwide, Inc. Silk protein treatment composition and treated substrate for transfer to skin
ATE363292T1 (de) * 1998-09-04 2007-06-15 Scios Inc Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren
EP1808160A3 (en) 1998-10-05 2008-03-05 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US6645947B1 (en) 1999-05-20 2003-11-11 Chitogenics, Inc. Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
DE19925519A1 (de) 1999-06-04 2000-12-07 Lohmann Therapie Syst Lts Wundauflage zur gesteuerten Abgabe von Wirkstoff an Wunden und Verfahren zu ihrer Herstellung
CA2377435A1 (en) * 1999-06-29 2001-01-04 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
US6500443B1 (en) * 1999-06-30 2002-12-31 Kimberly-Clark Worldwide, Inc. Delivery of a sacrificial substrate to inhibit protease permeation into skin
US6506394B1 (en) 1999-06-30 2003-01-14 Kimberly-Clark Worldwide, Inc. Delivery of a botanical extract to a treated substrate for transfer to skin
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
DE19957388A1 (de) 1999-11-24 2001-06-13 Michael Sittinger Chondroinduktive und implantierbare Substrate zur Knorpelheilung und -protektion
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
KR20010113918A (ko) * 2000-03-10 2001-12-28 추후제출 후안부 안과 질환을 치료하고 예방하기 위한 방법 및 조성물
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
KR20050008875A (ko) 2000-04-19 2005-01-21 시오노기세이야쿠가부시키가이샤 술폰아미드유도체의 제조방법 및 그의 결정
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US6503524B1 (en) 2000-06-16 2003-01-07 Kimberly-Clark Worldwide, Inc. Delivery of a skin health benefit agent to a treated substrate for transfer to skin
TWI305778B (en) 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
HK1077740A1 (en) 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
MXPA04008171A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7265097B2 (en) 2002-08-20 2007-09-04 Chitogenics, Inc. Methods of drug delivery using sulphated chitinous polymers
JP4777650B2 (ja) 2002-09-10 2011-09-21 アメリカン ナショナル レッド クロス 止血用包帯
JP2006347883A (ja) * 2003-09-08 2006-12-28 Neetec:Kk 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20120283232A9 (en) * 2003-11-12 2012-11-08 Zhengjun Wang Process for making a pharmaceutical composition
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20080260653A1 (en) * 2004-05-06 2008-10-23 Buttar Rashid A Transdermal Delivery Systems and Transdermal Chelation Preparations
ITMI20041376A1 (it) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
EP1787643A1 (en) * 2004-09-09 2007-05-23 Jimenez Bayardo, Arturo Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof
CA2584553A1 (en) * 2004-09-17 2006-03-23 Cellgentech, Inc. External agent for treatment of skin ulcer
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
BRPI0610704B8 (pt) 2005-05-27 2021-05-25 Bharat Biotech Int Ltd composição do fator de crescimento epidérmico, o processo para isso e sua aplicação
BRPI0613284A2 (pt) * 2005-06-17 2010-12-28 Genentech Inc métodos de aceleração de cicatrização de ferida
KR100687281B1 (ko) * 2005-11-30 2007-02-27 한국과학기술연구원 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
US20080033332A1 (en) 2006-08-04 2008-02-07 Macphee Martin Solid dressing for treating wounded tissue
ES2621876T3 (es) 2006-09-13 2017-07-05 Enhance Skin Products Inc. Composición cosmética para el tratamiento de la piel y procedimientos de la misma
KR100784134B1 (ko) 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
WO2009020612A1 (en) 2007-08-06 2009-02-12 Stb Lifesaving Technologies, Inc. Methods and dressing for sealing internal injuries
JP5123718B2 (ja) * 2008-04-15 2013-01-23 株式会社ゼロワン 茶殻等リサイクルシステム
IT1394690B1 (it) 2008-10-23 2012-07-13 Carli De Metodo di trattamento dermocosmetico della cute mediante applicazione di composizioni contenenti ngf.
RU2012133444A (ru) * 2010-01-06 2014-02-20 Орф Лифтаекни Хф Способ, применения стабильного фактора роста растительного происхождения в уходе за кожей
EP2353624A1 (en) 2010-02-10 2011-08-10 Université de la Méditerranée - Aix-Marseille II Embolic material, its process of preparation and its therapeutical uses thereof
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
WO2013043387A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
US9340783B2 (en) 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
EP2785335B8 (en) 2011-11-29 2017-08-02 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of darier disease
CN102512357A (zh) * 2012-01-11 2012-06-27 厦门大学 一种神经生长因子眼用凝胶及其制备方法
JP2015526515A (ja) 2012-08-31 2015-09-10 ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ オメガ３脂肪酸を有する眼用組成物
SG11201507429TA (en) 2013-03-15 2015-10-29 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AU2014254388B2 (en) 2013-03-15 2019-04-04 Synedgen Inc. Compositions and methods of use for wound healing
JP6871855B2 (ja) 2014-10-14 2021-05-19 サムエル リンチ， 創傷を処置するための組成物
EP3721868B1 (en) 2015-01-26 2022-06-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
WO2016170382A1 (en) 2015-04-23 2016-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
US20180353486A1 (en) 2015-12-01 2018-12-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of darier disease
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
US20200129486A1 (en) 2017-06-26 2020-04-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of olmsted syndrome
CA3088763A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
CR20200327A (es) 2018-01-26 2020-11-05 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
AU2019226085A1 (en) 2018-02-21 2020-09-17 Genentech, Inc. Dosing for treatment with IL-22 Fc fusion proteins
WO2020049327A1 (en) 2018-09-05 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of hidradenitis suppurativa in patients in need thereof
US20220031807A1 (en) 2018-09-27 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition reducing skin inflammation
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
WO2020074549A1 (en) 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2020239623A1 (en) 2019-05-24 2020-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ngal inhibitors for the treating chronic wound
WO2021013911A1 (en) 2019-07-24 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
JP2023554180A (ja) 2020-12-10 2023-12-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ジストロフィー性表皮水疱症を治療するための物質および方法。

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2047874A6 (ko) * 1969-06-10 1971-03-19 Nouvel Lucien
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
EP0137743A3 (en) * 1983-09-13 1986-10-01 Ed. Geistlich Söhne Ag Für Chemische Industrie Topically administrable pharmaceutical compositions
DE3380839D1 (en) * 1983-11-02 1989-12-21 J C R Kabushiki Kaisha Also Kn Ophthalmic preparations
CH662944A5 (it) * 1984-10-18 1987-11-13 Pier Luigi Prof Dr Luisi Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione.
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100231805B1 (ko) * 1997-01-09 1999-12-01 윤재승 인간상피세포 성장인자를 함유하는 피부외용제 조성물
KR100748390B1 (ko) * 2005-11-14 2007-08-10 주식회사 대웅 상피세포성장인자를 포함하는 상처치료용 서방성 필름 제형

Also Published As

Publication number Publication date
AU2223588A (en) 1989-03-23
JPH02112A (ja) 1990-01-05
EP0312208A1 (en) 1989-04-19
PT88541A (pt) 1989-07-31
GR1000250B (el) 1992-05-12
MX169808B (es) 1993-07-27
GR880100617A (en) 1989-06-22
NZ226171A (en) 1990-06-26
US5427778A (en) 1995-06-27

Similar Documents

Publication Publication Date Title
KR890004720A (ko) 성장 인자를 함유하는 겔 제형
EP0724888B1 (en) Wound covering material and wound covering composition
US5457093A (en) Gel formulations containing growth factors
KR100444417B1 (ko) 성장인자를함유하는겔제형
US6458386B1 (en) Medicaments based on polymers composed of methacrylamide-modified gelatin
Chvapil Considerations on manufacturing principles of a synthetic burn dressing: a review
US20060018955A1 (en) Method for preparing medical dressings
DE69013833T2 (de) Zusammensetzung und methode zur verhütung von verklebungen zwischen körpergewebe.
GB2314842A (en) Protein/oxidised regenerated cellulose complexes
Pandit et al. Investigation of acidic fibroblast growth factor delivered through a collagen scaffold for the treatment of full-thickness skin defects in a rabbit model
RU94030735A (ru) Композиционная мембрана, способ ее получения и способ направленной регенерации тканей с ее применением
NO831413L (no) Middel for levering av farmasoeytiske polypeptider.
DE69023163D1 (de) Natriumhyaluronat-Zusammensetzung.
JPH0776175B2 (ja) 損傷されたかまたは病気になった組織の局所的処置用の組成物および方法
Yaşayan et al. Natural polymers for wound dressing applications
Chvapil et al. Inert wound dressing is not desirable
Singh et al. Natural polymer-based thin film strategies for skin regeneration in lieu of regenerative dentistry
Burton et al. Collagen sponge for leg ulcers
Braund et al. Biomaterials as Platforms for Topical Administration of Therapeutic Agents in Cutaneous Wound Healing
CA2170600C (en) Wound covering material and wound covering composition
Blum Investigation of an adhesive albumin to enhance healing to full-thickness skin wounds
UA29890C2 (uk) Краплі для очей "вінісан"
RU98109421A (ru) Протезы кровеносных сосудов
AR004617A1 (es) Polimeros superabsorbentes para liquidos acuosos, procedimientos para su preparacion y su aplicacion

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid